Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
KPTI Stock Chart & Stats
$8.17
-$0.04(-5.28%)
At close: 4:00 PM EST
$8.17
-$0.04(-5.28%)
Day’s Range― - ―
52-Week Range$3.51 - $11.54
Previous CloseN/A
Volume220.82K
Average Volume (3M)228.24K
Market Cap
$144.10M
Enterprise Value$176.07M
Total Cash (Recent Filing)$45.88M
Total Debt (Recent Filing)$196.42M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Feb 12, 2026EPS Estimate
-2.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.82
Shares Outstanding18,310,284
10 Day Avg. Volume494,784
30 Day Avg. Volume228,238
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.44
Price to Sales (P/S)0.57
P/FCF Ratio-0.65
Enterprise Value/Market Cap1.22
Enterprise Value/Revenue1.24
Enterprise Value/Gross Profit1.29
Enterprise Value/Ebitda-2.19
Forecast
1Y Price Target
$12.40Price Target Upside51.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe Phase 1 study showed that Xpovio and Jakafi together reduced spleen volume significantly and improved symptom scores, which risk-mitigates the upcoming Phase 3 trial results.
Financial StabilityStrategic financing removes near-term financial overhang, upgrading to Buy.
Market AdoptionApproximately 75% of surveyed physicians have indicated their intent to adopt combination therapy, supporting the potential market acceptance.
Bears Say
Clinical RisksRisks to the stock include negative clinical data and delays in clinical development timelines.
Financial PerformanceKaryopharm reported a net loss per share larger than originally estimated for the third quarter.
Stock ValuationThe company's price target is lowered to $6 from $8, suggesting a less optimistic outlook on stock valuation.
Karyopharm Therapeutics News
KPTI FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Karyopharm Therapeutics lowest stock price was $3.51 and its highest was $11.54 in the past 12 months.
What is Karyopharm Therapeutics’s market cap?
Karyopharm Therapeutics’s market cap is $144.10M.
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is Feb 12, 2026 which is in 33 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Karyopharm Therapeutics released its earnings results on Nov 03, 2025. The company reported -$3.82 earnings per share for the quarter, missing the consensus estimate of -$3.466 by -$0.354.
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate is -2.08.
How many shares outstanding does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 18,310,284 shares outstanding.
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Karyopharm Therapeutics reported an EPS of -$3.82 in its last earnings report, missing expectations of -$3.466. Following the earnings report the stock price went up 4.655%.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Currently, no hedge funds are holding shares in KPTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Karyopharm Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.40 (51.77% Upside)
$12.40 (51.77% Upside)
Hedge Fund Trend
Decreased
By 8.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 23.9%
Last 30 Days ▼ 23.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-53.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-50.99%
Trailing 12-Months
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
KPTI Company Deck
KPTI Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and financial fortification, along with positive revenue growth and cost management. However, the net loss and the challenge of innovating within a stagnant market were concerns.View all KPTI earnings summariesKPTI Stock 12 Month Forecast
Average Price Target
$12.40
▲(51.77% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Lantern Pharma
―
Century Therapeutics
―
Medicus Pharma Ltd
―
Ownership Overview
3.38% Insiders
19.59% Mutual Funds
10.56% Other Institutional Investors
64.50% Public Companies and
Individual Investors